Sustained skin disruption in EB patients can lead to aberrant skin secretion with high circulating level of IL-1 that may potentially cause emaciation, vascular disorder, systemic amyloidosis and other visceral pathologies. This evidence concerns the gene IL1A and primary systemic amyloidosis.